BACKGROUND: Data are lacking regarding physical functioning, psychological well-being, and quality of life among colorectal cancer survivors >10 years postdiagnosis.
C olorectal cancer (CRC) is one of the most common cancers for men and women in both the United States and Canada. 1 Increased screening, earlier diagnosis, and improved treatments have resulted in declines in mortality by 4.5% annually, 2 and CRC survivors are living longer than ever. Five-year and 10-year relative survival rates are currently 65% and 58%. 2 yet, data are lacking regarding long-term physical functioning or quality of life (QoL).
Although several studies have examined CRC survivors within the first 5 years postdiagnosis, [3] [4] [5] [6] [7] few investigations detail QoL past this time point. Data from the National Surgical Adjuvant Breast and Bowel Project showed that survivors (median 8 years postsurgery) reported better physical and mental QoL but more fatigue than published norms. 8 Studies among survivors >5 years postdiagnosis show few significant QoL differences between survivors and normative data. 9 However, a lack of comparison groups limits these findings. One study examined 15-year survivors (N = 99) and, with the exception of worse diarrhea, found few differences compared with control subjects. 10 The current investigation examined differences in self-reported physical functioning, QoL, and psychological well-being among a population-based sample of long-term CRC survivors and unaffected control subjects. Directly comparing survivors with an age-and sex-matched control group allowed us to examine the extent to which problems were attributed to cancer as opposed to comorbidity and/ or older age. At 15 years postdiagnosis, we expected CRC survivors (vs age-and sex-matched unaffected control subjects) to report worse fatigue and bowel dysfunction but similar physical and mental QoL after adjusting for race, income, education, and other noncancer-related comorbid health conditions. We also examined QoL within subgroups based on tumor site, disease progression, and type of treatment.
PATIENTS AND METHODS

Participants and Procedures
Participants were recruited from the Ontario Familial Colorectal Cancer Registry (OFCCR), 1 of 6 international sites participating in the Consortium of Colon Cancer Familial Registries funded by the National Cancer Institute in 1997. 11 Procedures that established the survivor cohort have been published previously. 12 In brief, the population-based Ontario Cancer Registry was used to identify pathology-confirmed, incident CRC patients who were diagnosed between July 1, 1997, and June 30, 2000, and resided in the Ontario province. After the patient was identified from the pathology report, physicians were asked to permit contact, and then patients were mailed study information and consent forms to participate in the OFCCR. Unaffected population control subjects in the OFCCR were obtained through 2 methods, 12 random digit-dialing on Ontario telephone numbers from Bell Canada lists (1999) (2000) and random selection through the Ministry of Finance Property Assessment database, a populationbased listing of all Ontario residents (2001) (2002) . Control subjects were frequency matched within sex and 5-to 10-year age groups to the CRC survivors.
For the current investigation, both survivors and unaffected control subjects met the following criteria: 1) provided consent to participate in the OFCCR during 1997-2000, 2) showed through 2014 OFCCR records that the individual was alive with a current address; and 3) consented to participate in the current research project focused on QoL. Exclusion criteria included CRC survivor records without abstracted clinical data or report by an unaffected control of any type of cancer diagnosis since the initial recruitment.
Of the 1200 CRC survivors originally recruited by the OFCCR, 462 were reported through the registry as alive with current contact information and abstracted clinical data at the time of this study. Each survivor who returned a completed QoL questionnaire was matched with an unaffected control on sex and within 5 years of age. For survivors with multiple possible matches, 1 match was chosen at random. If the control did not return a completed questionnaire within 6 weeks of the initial mailing and had not responded to reminder telephone calls, a new control match was assigned. Of the unaffected control subjects, 912 (of the 1953 originally recruited) were reported through the registry to be alive and had current contact information, and 571 were able to be matched with survivors based on sex and age. Figure 1 displays the flowchart showing survey process and responses.
Both CRC survivors and unaffected control subjects were mailed an invitation letter and consent form, along with a packet of questionnaires and preaddressed and stamped return envelopes. On completion, participants were mailed a $30 gift card. Within 4 weeks of the initial questionnaire mailing, reminder calls were made to all of the nonrespondents. All of the study procedures were approved by the Mount Sinai Hospital research ethics board. was deceased or had incorrect contact information. Of the remaining 400 participants, 296 returned completed questionnaires (response rate = 74%). For the unaffected control subjects, 571 individuals were identified as potential matches who were eligible to receive surveys. After the initial mailing, 108 were found to be deceased, reported previous or current cancer, or had incorrect contact information. Of the 463 eligible, 255 returned completed questionnaires (response rate = 55.1%), providing age and sex matches for 86.1% of the survivors.
Measures
Bowel Dysfunction
Bowel dysfunction was assessed with the Memorial SloanKettering Cancer Center Scale (18 items), a gold standard for measuring bowel frequency, urgency, and dietary restrictions after CRC surgery, [13] [14] [15] with items rated from 1 (= always) to 5 (= never). The scale possesses good test-retest reliabilities for the scales (r, 0.62-0.87), good internal consistency (>0.70), and good discriminant and construct validity. 14, 15 Urinary Dysfunction Urinary dysfunction was assessed with the 4-item International Consultation on Incontinence Questionnaire-Short Form to measure urinary incontinence (eg, frequency, severity, and interference with daily life). 16 The International Consultation on Incontinence Questionnaire-Short Form has been used with bladder cancer 17 and prostate cancer 18 research samples, as well as healthy older adults, and shows excellent construct, convergent and divergent validity, sensitivity, and internal consistency (>0.95).
Fatigue
Fatigue was measured with the Functional Assessment of
Chronic Illness Therapy-Fatigue scale (13 items), commonly used in research with cancer patients and people with medical problems and is appropriate for use among healthy older adults. 19, 20 The intensity of fatigue and re- lated symptoms is rated on a scale from 0 (= not at all) to 4 (= very much). The scale has good psychometric properties with excellent internal consistency (>0.90), 19 good sensitivity (>0.90), and specificity (>0.69).
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Depression Depression was measured with the Center for Epidemiologic Studies-Depression (CES-D) scale, 21 a 20-item well-known and validated measure of clinical depression with both cancer samples 22 and older adults in the general population. 23 Each item is measured from 0 (= not at all) to 3 (= very often), where higher scores indicate more severe depressive symptoms. A cutoff score of ≥16 can also be used as an indication of a possible depressive disorder.
Quality of Life
QoL was measured with the Functional Assessment of Cancer Therapy-General (28 items), 24 which has 4 scales, physical, social, emotional, and functional well-being, and a combined total score (known as the FACT-G). Scores range from 0 to 108, with higher scores representing better QoL. Internal consistency and test-retest reliability are high (>0.89), and the scale shows good predictive, convergent, and divergent validity. Although survivors were well past the treatment phase, the FACT-G captures other relevant issues related to the cancer experience. These include cancer worry, coping, and lack of energy. 25, 26 Control subjects completed the Functional Assessment of Cancer Therapy-General Population scale, a 21-item version of the FACT-G designed for use with noncancer populations. 27 Scores from the 21 identical items are prorated to be comparable with the 28-item FACT-G. 27 
Clinical and Demographic Data
The OFCCR registry abstracted data on date of CRC diagnosis and clinical treatment including tumor site, surgery, chemotherapy, radiotherapy, cancer stage, and disease progression (ie, new primaries and recurrences). Age, sex, education, income, race, and marital status were also obtained from the OFCCR database for both CRC survivors and unaffected control subjects.
Comorbidities
All of the participants completed the Comorbidity Questionnaire, 28 a 12-item list of common medical conditions with good test-retest reliability (>0.90) that correlates well with the medical chart-based Charlson index (r = 0.63). Up to 3 points can be scored for each of 12 medical conditions (ie, presence, receipt of treatment for the condition, and condition causes functional limitation), for a possible total of 36 points.
Statistical Analysis
Paired t tests, McNemar tests, and tests of marginal homogeneity compared demographic and medical characteristics between matched pairs of CRC survivors and control subjects using SPSS version 22 (IBM Corp, Armonk, Ny). Linear mixed-effect models (using matched set as a random effect and CRC history as a fixed effect) compared the means between CRC survivors and control subjects on physical functioning, QoL, and well-being after adjusting for comorbidity, race, education, and income using all of the participants available. All of the variables included in the linear mixed-effect models were continuous. A conditional multivariate logistic regression model examined differences between matched sets in cutoff scores for depression on the CES-D, adjusting for comorbidity, race, income, and education. We further divided our survivors into subgroups based on treatment status (surgery, chemotherapy, or chemotherapy plus radiation), disease progression (diagnosis of a new primary), and tumor site (colon or rectal) and compared them with their corresponding matched control subjects for all outcomes.
RESULTS
Characteristics of the Sample
Sample characteristics are presented in Table 1 . The only statistically significant difference between survivors and control subjects was on race, with 96.6% of survivors versus 92.5% of unaffected control subjects identifying as white (McNemar test, p = 0.019). The average age of CRC survivors (mean = 73.2 y) and unaffected control subjects (mean = 72.8 y) was similar, and both groups were equally composed of women and men. For both groups, >80% were married, >50% had at least some college education, and just under 30% had a yearly household income of less than $40,000. Comorbidity index mean was 4.53 and 4.14 for survivors and control subjects. Among the CRC survivors, 77% were diagnosed with colon cancer. Approximately 72% of patients had either stage 1 or stage 2 cancer. All of the patients had undergone surgical resection, 53.4% had received chemotherapy, 19.9% had received radiotherapy, 21.3% had received a diagnosis of a new primary cancer (CRC or another site) since initial diagnosis, and 12.5% had a permanent stoma. Less than 5% had a recurrence of CRC. Survivors were 15.5 years postdiagnosis (range, 13.7-17.3 y).
Physical Functioning, QoL, and Psychological Well-Being Means and SEs calculated from the linear mixed models for survivors and control subjects are presented in Table 2 . Analyses revealed that survivors reported significantly greater dietary restrictions and more bowel urgency. Table 2 shows that higher scores indicate the likelihood of having fewer problems and that the magnitude of difference was small. Survivors were similar to their matched control subjects in reported bowel frequency, urinary dysfunction, and fatigue severity. Survivors were more likely to report significantly higher total QoL and higher QoL social well-being than control subjects. They also reported fewer depression symptoms relative to their matched control subjects. Descriptive analyses revealed no differences between the percentage of control subjects (19.0%) and survivors (19.3%) who met or exceeded the cutoff depression score of 16, (McNemar test, p = 0.82), a finding that remained when using a conditional multivariate logistic regression to adjust for covariates (OR = 1.08 (95% CI, 0.57-1.52); p = 0.77). No significant differences emerged between survivors and control subjects on QoL emotional well-being, functional well-being, or physical well-being.
Subgroup Analyses
Survivors were additionally stratified based on treatment status, disease progression, and tumor site and were compared with control subjects. As shown in Table 2 , the pattern of significant findings for all outcomes was similar within all of the subgroups. Because findings were identical in the chemotherapy-only and the chemotherapy plus radiotherapy group, the 2 groups were combined. Across treatment type, survivors reported significantly more dietary restrictions and bowel urgency than control subjects. Survivors also reported significantly higher social QoL in both treatment subgroups and total QoL, although the difference was not statistically significant in the surgery-only subgroup. Similar to the overall sample, survivors in both treatment subgroups reported significantly fewer depression symptoms than control subjects. Among survivors who had a new primary cancer diagnosis over time, only dietary restrictions were significantly worse compared with control subjects. With regard to tumor site, the pattern of findings for survivors compared with control subjects was identical to that for the full sample within both the colon and rectal cancer subgroups (data not shown). Finally, to explore potential sex differences, models stratified by sex (men versus women) revealed results identical to the nonstratified analyses for all outcomes (data not shown).
DISCUSSION
To our knowledge, this is the largest population-based study examining physical functioning, QoL, and wellbeing in CRC survivors ≥15 years postdiagnosis. Findings reveal equivalent physical, emotional, and functional QoL and similar fatigue and urinary dysfunction for CRC survivors compared with their age-and sex-matched unaffected control subjects.
Previous studies also show that CRC survivors are similar to those unaffected by cancer on physical and psychosocial QoL measures. For example, one study of female-only CRC patients found that QoL was comparable to published age-specific norms on all scales of the Short Form-36. 29 Moreover, QoL scores among long-term male and female CRC survivors (80% of whom were <15 years postdiagnosis) were comparable to or higher than published norms. 30 These findings differ from studies of survivors within the first 5 years of diagnosis, which show significant problems in QoL (pain and physical functioning). 3, 31 However, problems appear to largely resolve over the long term, 32, 33 with the exception of bowel dysfunction. Our findings suggest that QoL is good for CRC survivors, even after considering the effect of tumor site, disease progression, treatment, or sex. This corresponds with findings from a small (N = 99) population-based study in France 10 of CRC survivors 15 years postdiagnosis, who significantly differed from control subjects only on diarrhea but not on overall QoL, fatigue, or anxiety. A German population-based study, 34 in contrast, found that CRC patients over the age of 70 years reported worse QoL than control subjects on role, social, cognitive, and emotional functioning, in addition to worse bowel functioning. However, this study used historical control subjects who reported their QoL 10 years before survivors. Moreover, survivor QoL was comparable to population-based published norms. The current study is the largest in a North American sample to demonstrate equivalent QoL in a tightly controlled, population-based cohort of long-term survivors and control subjects assessed within the same time frame.
4
The current study also provides novel information regarding the significantly higher social QoL of survivors compared with control subjects, which meets the minimally important difference criteria of 2 to 3 points on this scale. 35 Our study is the first to demonstrate this in patients with CRC. Little research has examined social QoL or depression in long-term survivors. Higher social QoL for survivors may be related to increased social support garnered during the treatment and survivorship phase of CRC. In other studies, patients with cancer have also reported greater social support compared with healthy control subjects. 36, 37 Regarding depression, a study examining the National Comorbidity Survey-Replication sample found those ≥5 years postcancer diagnosis had no increased risk of depression compared with people without cancer. 38 Our sample found that survivors reported significantly lower mean CES-D scores than control subjects, however, the scores for both groups indicate little depression. Taken together, the findings suggest that social QoL and depression are not significant problems for long-term CRC survivors.
The areas where survivors reported comparative deficits were in bowel urgency and dietary restrictions, but these differences were relatively small in magnitude. Worse bowel functioning in the short and long term after CRC diagnosis has been consistently reported. 5, 8, 10, 30, 34 Clinicians need to inform patients when bowel dysfunction is an expected long-lasting problem, and symptom selfmanagement interventions may help patients cope with these problems. 39, 40 Strengths of the current study are the use of age-and sex-matched, population-based unaffected control subjects; analyses that adjusted for income, education, race, and comorbidities; excellent response rates on the QoL survey for survivors; well-validated cancer-specific measures; and survivors and control subjects recruited from a population-based registry. This study also compared differences by tumor site, type of treatment, disease progression, and sex as possible contributors to QoL; specificity had been lacking in previous research. Some limitations, however, should be noted. No baseline assessment was available to examine change in outcomes over time. The few published longitudinal studies show that, although patients report worse QoL 1 year postsurgery compared with control subjects, 31 QoL tends to improve over time.
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It is also possible that response shift may account for good QoL in the long term, because research shows that positive self-evaluations often follow a cancer diagnosis. 32 Nonrandom dropout of survivors by 15 years postdiagnosis is also a limitation. It is possible that participating survivors had low comorbidity levels, because previous data show that comorbidity is related to all-cause death in patients with cancer. 41 Moreover, those who survive for 15 years are the healthiest, reflected by earlier-stage disease in this sample. Previous data demonstrate that stage 4 patients typically have the worst QoL and depression scores, 31 so our findings likely underestimate difficulties for the entire sample during these earlier years. In addition, a lower response rate for unaffected control subjects compared with survivors suggests that healthier control subjects may have been more likely to participate, which also limits the generalizability of the findings. Furthermore, because the participation rate for CRC survivors was moderate (61% for the first year of the OFCCR registry), 12 it is possible that healthier individuals participated in the registry and thus our survivor sample is skewed toward persons with better QoL and well-being. However, both survivors and control subjects were similar to participants in the larger OFCCR registry with regard to demographic variables. 42 None of these limitations detract meaningfully from the validity and importance of the findings. Healthcare providers should be aware that bowel dysfunction may be an ongoing issue for CRC survivors even 15 years after diagnosis, with a small difference from their age-and sexmatched control subjects. Moreover, the overall message is encouraging: healthcare providers can reassure CRC survivors that, with the exception of bowel symptoms, QoL is similar to those who have not had cancer.
